Prevalence of Potentially Clinically Significant Drug–Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature

Autor: Daryl Hodge, Eva Maria Hodel, Elen Hughes, Phoebe Hazenberg, Sandra Grañana Castillo, Sara Gibbons, Duolao Wang, Fiona Marra, Catia Marzolini, David Back, Saye Khoo

Publikováno v: JAIDS Journal of Acquired Immune Deficiency Syndromes. 92:97-105

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9df22b47092723a3442fe740076f09cf
https://doi.org/10.1097/qai.0000000000003122

Safe co‐administration of direct‐acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study

Autor: Kathryn McDaniel, Alyssa E. Utz, Mikhail Akbashev, Katherine G. Fuller, Alison Boyle, Katherine Davidson, Fiona Marra, Sital Shah, Emily J. Cartwright, Aakriti A. Arora, Sarah DuPont, Lesley S. Miller

Publikováno v: Journal of Viral Hepatitis. 29:1073-1078

Treatment for hepatitis C virus (HCV) with direct-acting antivirals (DAA) is advantageous over previous treatment options due to high efficacy, short treatment duration, and relatively few drug interactions. Similarly, direct oral anticoagulants (DOA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::819ee1c8d0a9c509df899195bbc0b360
https://doi.org/10.1111/jvh.13750

Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir

Autor: Zhenzhen Zhang, Yves Horsmans, Francesco Negro, Nasser Semmo, Fiona Marra, Carlos Roncero, Nuno Marques, Michael Gschwantler, Włodzimierz Mazur, Rawi Hazzan, Mark Bondin, Georges Philippe Pageaux, Robert Flisiak, Konstantinos Mimidis, Tarik Asselah, Harald Hofer, Suzanne Bourgeois, John Marcinak, Pietro Lampertico, Alessio Aghemo, Ella Veitsman, Ioannis Goulis

Publikováno v: Aghemo, Alessio; Horsmans, Yves; Bourgeois, Stefan; Bondin, Mark; Gschwantler, Michael; Hofer, Harald; Semmo, Nasser; Negro, Francesco; Zhang, Zhenzhen; Marcinak, John; Veitsman, Ella; Hazzan, Rawi; Mimidis, Konstantinos; Goulis, Ioannis; Marques, Nuno; Flisiak, Robert; Mazur, Wlodzimierz; Roncero, Carlos; Marra, Fiona; Pageaux, Georges Philippe; ... (2021). Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir. Infectious diseases and therapy, 10(4), pp. 2203-2222. Springer 10.1007/s40121-021-00455-1
Infectious diseases and therapy, Vol. 10, no.4, p. 2203-2222 (2021)
Infectious Diseases and Therapy
Infectious Diseases and Therapy (2021)

Introduction Glecaprevir/pibrentasvir is approved for treating chronic hepatitis C virus (HCV) genotypes (GT) 1–6. We evaluated real-world effectiveness, safety, and patient-reported outcomes of glecaprevir/pibrentasvir in underserved patient popul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97bff272ab6e3dd79841032716fb8d2a
https://doi.org/10.1007/s40121-021-00455-1

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Autor: Pietro Lampertico, Heiner Wedemeyer, Marcello Persico, Fiona Marra, Kristina Lohmann, Steven L. Flamm, Mark Bondin, Steven E Marx, Stephen T. Barclay, Zhen Zhen Zhang, Pamela S. Belperio, Stefan Mauss

Publikováno v: Advances in Therapy
ADVANCES IN THERAPY

Introduction: More than 70 million people are estimated to be infected with hepatitis C virus globally. Glecaprevir/pibrentasvir is a widely used treatment and has recently been approved for an 8-week regimen for treatment-naïve patients with compen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84815f3c681f3412b431006e0fa7968e
http://europepmc.org/articles/PMC7547986

Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions

Autor: Catia Marzolini, Daniel R. Kuritzkes, Fiona Marra, Alison Boyle, Sara Gibbons, Charles Flexner, Anton Pozniak, Marta Boffito, Laura Waters, David Burger, David Back, Saye Khoo

Publikováno v: Annals of Internal Medicine C.2, 175, 5, pp. 744-746
Annals of Internal Medicine C.2, 175, 744-746

Item does not contain fulltext Nirmatrelvir–ritonavir (NMV/r) is now being used to treat high-risk patients with mild to moderate COVID-19. This article provides advice to clinicians regarding recognition of medications likely to interact with NMV/

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1661415368f1999c23a15cb35ce55cf4
https://pubmed.ncbi.nlm.nih.gov/35226530